Quick Answer
MYRIAD GENETICS INC reported Cash and Equivalents of $149.60 million for fiscal year 2025.
MYRIAD GENETICS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $149.60M | +46.1% |
| 2024 | $102.40M | -22.5% |
| 2023 | $132.10M | +132.2% |
| 2022 | $56.90M | -77.9% |
| 2021 | $257.40M | +120.0% |
| 2020 | $117.00M | -28.5% |
| 2020 | $163.70M | +75.6% |
| 2019 | $93.20M | -16.0% |
| 2018 | $110.90M | +8.3% |
| 2017 | $102.40M | +49.5% |
| 2016 | $68.50M | +6.9% |
| 2015 | $64.10M | -1.1% |
| 2014 | $64.80M | -37.8% |
| 2013 | $104.10M | +20.5% |
| 2012 | $86.40M | +64.0% |
| 2011 | $52.68M | -43.3% |
| 2010 | $92.84M | +46.2% |
| 2009 | $63.51M | -73.3% |
| 2008 | $237.73M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $145.40M | +45.5% | +95.4% |
| June 30, 2025 | $74.40M | -19.5% | -19.0% |
| March 31, 2025 | $91.80M | -5.3% | -10.4% |
| December 31, 2024 | $102.40M | -22.5% | +2.5% |
| September 30, 2024 | $99.90M | +31.4% | +8.1% |
| June 30, 2024 | $92.40M | -10.1% | -4.6% |
| March 31, 2024 | $96.90M | +80.8% | -26.6% |
| December 31, 2023 | $132.10M | +132.2% | +73.8% |
- MYRIAD GENETICS INC showed an increase of +46.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, MYRIAD GENETICS INC’s cash and equivalents has declined by 37.1% (from $237.73 million to $149.60 million).
- The most recent figure is from MYRIAD GENETICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: